Investor & Media Home
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Learn more about our pipeline here.
Recent News
Aug 8, 2022
Jul 21, 2022
Jun 30, 2022
FRONT >> News > View All
View All Press Releases
Events & Presentations
Jun 30, 2022 at 6:30 PM EDT
Jun 8, 2022 at 8:30 AM EDT
May 10, 2022 at 12:30 PM EDT
FRONT > Events - View All
View All Events
Corporate Presentation
More information is coming soon.
FRONT >> Presentations > View All
View Here Presentations